Enanta Pharmaceuticals (NASDAQ:ENTA) Rating Lowered to “Sell” at Wall Street Zen

Posted by Brian Himes on Aug 24th, 2026

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

ENTA has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, June 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $19.50.

Check Out Our Latest Report on Enanta Pharmaceuticals

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $13.47 on Friday. The firm has a market capitalization of $392.25 million, a PE ratio of -5.59 and a beta of 0.98. The stock has a 50 day moving average of $13.43 and a 200-day moving average of $13.46. Enanta Pharmaceuticals has a 52 week low of $7.05 and a 52 week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The company had revenue of $14.36 million for the quarter, compared to analyst estimates of $16.76 million. Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%. As a group, analysts predict that Enanta Pharmaceuticals will post -2.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ENTA. Deutsche Bank AG increased its holdings in shares of Enanta Pharmaceuticals by 4.6% during the 4th quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company’s stock valued at $380,000 after acquiring an additional 1,055 shares during the last quarter. Public Employees Retirement System of Ohio boosted its holdings in Enanta Pharmaceuticals by 8.3% during the third quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 1,100 shares during the period. Ameriprise Financial Inc. lifted its position in shares of Enanta Pharmaceuticals by 8.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 1,383 shares during the last quarter. Quantinno Capital Management LP boosted its stake in Enanta Pharmaceuticals by 4.9% during the 1st quarter. Quantinno Capital Management LP now owns 35,122 shares of the biotechnology company’s stock valued at $444,000 after purchasing an additional 1,627 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in Enanta Pharmaceuticals by 13.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock valued at $197,000 after buying an additional 1,940 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

(Get Free Report)

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.